Skip to main content

Specimen Collection Manual and Test Catalog

  or
  or
  or

EBV NUCLEAR ANTIGEN IGG ANTIBODY

Geisinger Epic Procedure Code:  LAB2232    Geisinger Epic ID:  7431

SPECIMEN COLLECTION
Specimen type: 

Serum


Preferred collection container: 
Alternate collection container: 
6 mL red-top (plain, non-serum separator) tube
Specimen required: 

0.5 mL serum; minimum 0.2 mL



SPECIMEN PROCESSING
Processing instructions: 

Allow to clot. Centrifuge and submit 0.5 mL serum.


Transport temperature: 

Refrigerated (preferred). Room temperature (stable 8 hours) or frozen specimen also acceptable.


Specimen stability: 

Room temperature: 8 hours. 2-8°C: 96 hours. Frozen: 6 months


Rejection criteria: 

Specimen stability exceeded; specimen grossly hemolyzed.



TEST DETAILS
Interpretation guide: 
ResultInterpretation
NegativeAbsence of detectable EBNA IgG antibodies. A negative result generally excludes past EBV infection. If exposure to Epstein-Barr virus is suspected despite a negative finding, a second sample should be collected and tested no less than one to two weeks later.
EquivocalSuggest a second sample be collected and tested one to two weeks later.
PositivePresence of detectable EBNA IgG antibodies. A positive result is indicative of past infection.

CPT code(s):  86664
Note: The billing party has sole responsibility for CPT coding.  Any questions regarding coding should be directed to the payer being billed.
The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only.

Test includes: 

ualitativ


Methodology: 
Chemiluminescence
Synonyms: 

EBNA, Epstein Barr IgG antibody to nuclear antigens, Epstein Barr Nuclear Antigen, Epstein Barr Virus, EBV-EBNA, EBNAAB, EBV Serology, EBNA, EBV Antibody, EBNA IgG Antibody, Epstein Barr Nuclear Antigen IgG


Clinical significance: 

Epstein-Barr virus (EBV) is responsible for infectious mononucleosis (IM) and has also been implicated in Burkitt's lymphoma and nasopharyngeal carcinoma. EBV-NA (Epstein-Barr virus nuclear antigen) IgG antibodies appear during the convalescent phase of IM and remain present throughout life. A positive EBV-NA IgG antibody in a healthy individual indicates past immunological exposure to EBV.


Doctoral Director(s): 
Benjamin Andress, PhD, DABCC
Hoi-Ying Elsie Yu, PhD, DABCC, FADLM
Review Date:  12/05/2024

Performing Locations